IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced the publication of ...

Clinical characteristics were associated with different survival outcomes in patients treated with immune checkpoint ...

Patients with MSI-H mCRC had a higher probability of survival with first-line ICI therapy than with chemotherapy, but second-line or later ICIs did not confer the same benefit.

Solnerstotug continues to be well tolerated, with no dose-limiting toxicities and the majority of AEs Grade 1 or 2 in severity. Out of 60 patients, there have been four (7%) cases of Grade 1 cytokine ...

As a tumor-agnostic biomarker, MSI is relevant to a vast majority of cancer patients, with up to 13 million individuals worldwide potentially eligible for this diagnostic approach each year.

This €1.6 Million financing will allow MSInsight to finalize MSIcare's technological development, demonstrate its performance in various types of cancer, and initiate the regulatory clinical ...

The results showed immune checkpoint inhibitors greatly improved survival rates for patients living with metastatic MSI-H colorectal cancer, in line with clinical trials. Investigators also found ...

This €1.6 Million financing will allow MSInsight to finalize MSIcare’s technological development, demonstrate its performance in various types of cancer, and initiate the regulatory clinical ...